Discovering and developing novel drugs for cancer treatment

Terpenoid Therapeutics, Inc. is a privately-held biotechnology company focused on anti-cancer therapeutics. We use the platform of terpene chemistry to develop candidate drug molecules. Our team is creating, testing, and developing novel drug candidates using cutting-edge technologies. We seek to generate a robust pipeline of terpene-derived therapeutic agents. Two projects are in advanced preclinical testing with lead compounds identified in both projects.

Technology

Terpenoid's bisphosphonate project is based on proprietary terpenoid-modified bisphosphonate inhibitors of geranylgeranyl diphosphate synthase (GGDPS), a novel target for which there are currently no approved drugs. Terpenoid predicts that inhibition of GGDPS will result in efficacy in the treatment of primary tumors and metastases (including, but not limited to, bone metastases).

Terpenoid's schweinfurthin project is focused on discovering and developing a drug with activity against primary tumors and metastases. This project is based on rare schweinfurthin natural products whose unique profile of anti-cancer activity was first reported by the National Cancer Institute in 1998

A novel small molecule in the Terpenoid Therapeutics Inc. (TTI) pipeline reduces the progression of pulmonary fibrosis in a mouse model that is accepted as a basis for human drug approval for this disease. The results are published as a manuscript titled “Targeting the isoprenoid pathway to abrogate progression of … Read more →

A novel small molecule in the Terpenoid Therapeutics Inc. (TTI) pipeline reduces metastases in a mouse model of prostate cancer. The results are published as a manuscript titled “Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis,” which recently appeared in the journal Clinical … Read more →

TTI was recently mentioned in this article in the Cedar Rapids Gazette By Dave DeWitte …Several presenters were established businesses that are looking for funding, resources or ideas to let them grow. Terpenoid Therapeutics’ Raymond Hohl seemed to dazzle his critique panel at the Seed and Venture Forum with his … Read more →